The record provides preclinical evidence that restoring reduced glomerular angiopoietin-1 through kidney-targeted mRNA delivery can slow WT1-associated glomerular injury; it remains an inference that this approach will be safe, technically feasible, and disease-modifying in children.

The reviewed evidence supports molecular profiling as a tool for diagnosis and risk stratification and indicates that selected infants—particularly those with favorable-risk SHH-activated medulloblastoma—may benefit from regimens that delay or avoid craniospinal irradiation; it remains an inference requiring prospective validation that subgroup-specific targeted therapies, immunotherapy, liquid biopsy, and other emerging approaches will improve survival or neurodevelopmental outcomes across these rare tumors.

Evidence supports the hypothesis that first-line intra-arterial chemotherapy may improve eye preservation compared with intravenous chemotherapy in children with retinoblastoma; inferring a preferred regimen or added value from combined intravenous and intra-arterial treatment remains premature because survival, toxicity, recurrence, metastasis, and long-term outcomes are uncertain or inadequately reported.

The study provides preliminary evidence that broad leukemia-associated mutation clearance may identify patients who can achieve favorable relapse-free survival with HiDAC consolidation; it remains an inference, requiring randomized confirmation, that this strategy can safely select patients for chemotherapy rather than allogeneic transplantation.

The study provides clinical evidence that single-dose oral NEPA can prevent CINV in pediatric patients receiving moderately or highly emetogenic chemotherapy; it is reasonable but still inferential that the 4 mg/kg netupitant dose may offer more reliable delayed-phase control, because the reported response rates were similar between dose groups and the exposure-response finding was described only as a trend.

The reported evidence associates topical B-VEC treatment with meaningful wound improvement in three patients; it is reasonable—but not established by this uncontrolled series—to hypothesize that HSV1-mediated delivery of full-length COL7A1 can promote durable wound closure and reduce wound burden when integrated with comprehensive supportive care.

The supplied evidence supports proton therapy as a clinically used radiotherapy approach with favorable pooled outcomes, while the proposal that modern intensity-modulated proton dose escalation could improve control after subtotal resection remains an untested hypothesis requiring prospective comparative evaluation.

The reported responses support the preliminary hypothesis that tumour stem cell membrane microparticle loading may enhance DC–CIK targeting of refractory T/NK-cell malignancies; however, comparative studies are required to determine whether the cellular product caused the responses, improves durability, or is acceptably safe.

Evidence summarized in the record supports matching MAPK-pathway alterations or actionable ALK, NTRK, ROS1, and MET fusions to selective inhibitors in relevant pediatric glioma subgroups; it is an inference—not directly demonstrated by this review—that improved brain penetration and strategies against adaptive resistance could extend precision-treatment benefits to currently refractory pHGGs and DMGs.

The reported clinical outcomes support seven-day venetoclax plus dose-adjusted intensive chemotherapy as a potentially active induction strategy; it may preserve efficacy while reducing myelosuppression relative to longer venetoclax schedules, but that comparative safety advantage is an inference because no longer-duration control group or detailed toxicity comparison is reported.

The trial provides evidence that immersive virtual reality can improve short-term chemotherapy-related symptom control in children; it may act as a scalable nonpharmacologic adjunct through distraction or reduced anticipatory distress, but that mechanism was not directly tested in the supplied record.

The reported comparative response signals support the hypothesis that selected PD-1/PD-L1 inhibitor combinations may improve response rates in Hodgkin lymphoma; however, this is an inference from aggregate and network comparisons, not proof of superiority, safety, survival benefit, or pediatric-specific efficacy.